https://pubmed.ncbi.nlm.nih.gov/39448554/ MASLD

Acta Paediatr. 2024 Oct 24.
doi: 10.1111/apa.17475. Online ahead of print.

Irisin as a marker of hepatic steatosis in children with metabolic dysfunction-associated steatotic liver disease

Katarzyna Zdanowicz 1, Natalia Kopiczko 1, Marta Flisiak-Jackiewicz 1, Anna Bobrus-Chociej 1, Monika Kowalczuk-Kryston 1, Dariusz Marek Lebensztejn 1
Affiliations expand
PMID: 39448554

DOI: 10.1111/apa.17475
Abstract

Aim: The purpose of this study was to evaluate irisin, myonectin and high-sensitivity interleukin-6 (hs IL-6) levels in obese children and adolescents and to determine the association of these parameters with metabolic dysfunction-associated steatotic liver disease (MASLD) in children.

Methods: Sixty-one overweight/obese children with suspected liver disease and seventeen healthy controls were included in the study. MASLD was diagnosed according to the latest consensus. Circulating irisin, myonectin and hs IL-6 were measured by enzyme-linked immunosorbent assay (ELISA).
Results: The study group included 38 children meeting MASLD criteria and 23 children without diagnosed hepatic steatosis. The concentrations of the analysed myokines were comparable in the MASLD and non-MASLD groups. Patients with MASLD were further divided according to the severity of hepatic steatosis. Significantly higher levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyltransferase, uric acid and irisin were observed in patients with severe hepatic steatosis compared to mild hepatic steatosis. There were borderline statistically significant positive correlations of irisin with ALT and AST.

Conclusion: We revealed that elevated irisin levels were associated with the degree of hepatic steatosis in MASLD. We also found a borderline significant positive association of irisin with liver enzymes.